CJC-1295 FAQ: 28 Questions from the Research Literature
Frequently Asked Questions: CJC-1295
These questions are drawn from published PAA data, Quora, and search-suggestion sources. Every quantitative claim is sourced to a numbered citation in the references.
What is CJC-1295?
CJC-1295 is a 29-amino-acid synthetic analog of growth hormone-releasing hormone (GHRH), first synthesized by ConjuChem Biotechnologies. It was investigated in Phase I/II human trials for adult GH deficiency and body composition endpoints. Four amino acid substitutions confer resistance to DPP-IV degradation; the DAC form adds albumin-binding for an extended half-life of 5.8–8.1 days [1][4]. CJC-1295 is not FDA-approved for any indication.
What does CJC-1295 do to the body?
CJC-1295 binds GHRH receptors in the anterior pituitary, stimulating pulsatile release of endogenous growth hormone via the Gs-cAMP-PKA-calcium signaling cascade. Downstream, GH drives hepatic IGF-1 synthesis. In the Teichman 2006 Phase II trial, single doses elevated mean plasma GH 2- to 10-fold for 6+ days and IGF-1 by 1.5- to 3-fold for 9–11 days [1].
What is the difference between CJC-1295 with DAC and without DAC?
The DAC (Drug Affinity Complex) modification adds a lysine-reactive maleimide group that covalently binds albumin, extending plasma half-life from approximately 30 minutes (no-DAC) to 5.8–8.1 days (DAC) in published human pharmacokinetic studies [1]. No-DAC (Modified GRF 1-29) retains DPP-IV resistance from the four amino acid substitutions but clears from circulation far faster than the albumin-conjugated form.
What are the side effects of CJC-1295?
Adverse events documented in published studies include injection-site reactions, transient flushing and vasodilation (at 90–125 mcg/kg in the Teichman 2006 trial [1]), headache, water retention, and elevated appetite. The FDA raised immunogenicity concerns for compounded injectable CJC-1295 in 2024. A Phase II trial was halted in 2006 following a participant death [18].
Does CJC-1295 affect testosterone?
No direct testosterone-raising mechanism has been identified. CJC-1295 targets the GH/IGF-1 axis exclusively; no direct testosterone elevation has been demonstrated in peer-reviewed studies. Some animal research notes indirect anabolic signaling through IGF-1 that may interact with androgen receptor pathways, but no testosterone elevation has been measured in CJC-1295 trials.
How does CJC-1295 work?
CJC-1295 mimics the N-terminal active fragment of native GHRH(1-29), binding GHRH-R on somatotroph cells and triggering calcium-mediated GH exocytosis. Four substitution mutations (Ala2, Gln8, Ala15, Leu27) confer protease resistance absent in the native peptide [11]. The Ala2 substitution specifically blocks DPP-IV cleavage. The DAC modification then adds covalent albumin binding for extended half-life.
What is CJC-1295 ipamorelin good for?
In preclinical and early clinical research, the CJC-1295 plus ipamorelin combination is studied for synergistic amplification of GH pulse amplitude. CJC-1295 increases baseline GH secretion via GHRH-R; ipamorelin (a GHSR agonist) triggers an acute GH pulse via a distinct receptor. Co-activation of both receptors doubled cAMP response vs. GHRH-R alone in vitro [8]. Body composition and fat metabolism outcomes are studied in preclinical models [9][10].
What are the side effects of CJC-1295 and ipamorelin?
Combined use adverse events reported in clinical and observational data include injection-site erythema, flushing, transient headache, increased hunger, joint discomfort, and water retention. Ipamorelin monotherapy produced no significant ACTH or cortisol release in swine at doses more than 200-fold above the GH-effective dose [7]. CJC-1295 was well tolerated at 30–60 mcg/kg in the Teichman 2006 trial [1].
How long does CJC-1295 take to work?
Pharmacokinetic studies in humans showed peak plasma GH elevation within 2–6 hours of a single subcutaneous injection. Mean plasma GH levels remained elevated for 6 days post-injection in the CJC-1295 DAC arm of the Teichman et al. 2006 Phase II trial [1]. IGF-1 elevation was sustained for 9–11 days post-injection.
Is CJC-1295 safe?
The Teichman 2006 Phase II trial reported CJC-1295 well tolerated at 30–60 mcg/kg with no serious adverse reactions [1]. A Phase II trial in HIV patients with visceral obesity was halted in 2006 following a participant death [18]. The FDA placed CJC-1295 on the 503A compounding no-go list in 2024 citing immunogenicity concerns. This site documents the research literature only.
How do I use CJC-1295 and ipamorelin?
Published dosing protocols in human trials used subcutaneous administration; preclinical rodent studies used intraperitoneal injection at 30–500 mcg/kg [1][9]. This site summarizes published literature only. CJC-1295 is not FDA-approved and no validated human therapeutic protocol exists. The CJC-1295 dosage in published trials page covers what the studies actually administered.
Which is better, CJC-1295 with or without DAC?
The two variants serve different research models: DAC (long-acting, weekly dosing in studies) and no-DAC (also called Modified GRF 1-29, short-acting, pulsatile-dosing models). The Teichman 2006 study used the DAC form in humans [1]; no direct head-to-head efficacy trial has been published. No superiority conclusion is supported by the available evidence.
What are the potential side effects of using peptides such as CJC-1295 to build muscle mass?
Research on muscle-building peptides documents acromegaly-like risks with supraphysiological GH elevation (soft tissue overgrowth, insulin resistance), injection-site complications, and glucose metabolism disruption. CJC-1295 studies in rodents observed dose-dependent IGF-1 elevation without overt organ toxicity at standard research doses [5], but the acromegaly literature establishes physiological risks of sustained GH excess.
Does CJC-1295 raise testosterone?
No direct testosterone-raising mechanism has been identified in published studies. CJC-1295 targets the GH/IGF-1 axis exclusively. Some animal research has noted indirect anabolic signaling through IGF-1 that may interact with androgen receptor pathways, but no testosterone elevation has been measured in CJC-1295 trials. The HPG axis (which governs testosterone) is not a primary target of CJC-1295.
Is CJC-1295 FDA approved?
CJC-1295 is not FDA-approved for any indication. It was listed by the FDA in 2024 on the bulk drug substance no-go list for Section 503A compounding pharmacies, citing no clinical necessity demonstrating advantage over approved alternatives and immunogenicity concerns for injectable formulations from potential peptide aggregation.
What is the CJC-1295 half-life?
Published pharmacokinetic data: CJC-1295 without DAC has a plasma half-life of approximately 30 minutes in rodent models; CJC-1295 with DAC demonstrated a mean half-life of 5.8–8.1 days in the Teichman et al. Phase II human trial (2006, JCEM) [1]. Native GHRH(1-29) (sermorelin) has a half-life of approximately 10–20 minutes in humans [13].
Will CJC-1295 and ipamorelin give good results for weight loss and muscle building?
Rodent studies with GHRH analogs and GHSR agonists separately report reductions in adipose tissue and preservation of lean body mass. Ipamorelin produced dose-dependent bone growth and body weight gain in rats [9][10]; CJC-1295 restored normal body composition in GH-deficient mice [5]. No randomized controlled trial in humans has examined the CJC-1295/ipamorelin combination specifically for weight loss or muscle building as primary endpoints.
What is the CJC-1295 mechanism of action?
CJC-1295 binds GHRH-R on anterior pituitary somatotrophs, activating adenylate cyclase via Gs-coupling, elevating intracellular cAMP, and triggering calcium-dependent GH secretory granule exocytosis [15]. Four substitution mutations (Ala2, Gln8, Ala15, Leu27) confer in vivo stability by resisting DPP-IV and endopeptidase cleavage [11]. The cryo-EM structure of the GHRH-GHRH-R-Gs complex was resolved at 2.6 Angstrom in 2020 [12].
Is CJC-1295 a steroid?
CJC-1295 is a peptide, not a steroid. It is a 29-amino-acid polypeptide with no steroidal ring structure. Its mechanism — GHRH receptor agonism triggering the Gs-cAMP-PKA-calcium cascade — is entirely distinct from androgenic/anabolic steroids, which act on nuclear androgen receptors. The two compound classes differ in structure, target receptor, and mechanism.
Does CJC-1295 cause hair loss?
No published study has identified hair loss as a direct adverse event of CJC-1295. Elevated IGF-1 has theoretical associations with androgenic pathways in some models, but no clinical or preclinical data specifically links CJC-1295 to alopecia. Hair loss does not appear in the adverse event records of the published human trials [1][3].
How does CJC-1295 compare to sermorelin?
Sermorelin is the first 29 amino acids of native GHRH with no protective substitutions, yielding a plasma half-life of 10–20 minutes [13]. CJC-1295 carries four mutations and the optional DAC modification, extending half-life from approximately 30 minutes (no-DAC) to 5.8–8.1 days (DAC). No direct head-to-head clinical trial has been published. The sermorelin vs CJC-1295 distinction is structural and pharmacokinetic, not based on comparative efficacy data.
How long does CJC-1295 stay in your system?
CJC-1295 without DAC is largely cleared within 4–6 hours in rodent models. The DAC form demonstrated sustained elevation of mean plasma GH and IGF-1 concentrations for up to 14 days post-injection in the 2006 human Phase II study [1]. Detection studies confirm CJC-1295 measurable in human plasma at below 50 pg/mL using immunoaffinity-assisted LC-HRMS [20] and in equine plasma at 180 pg/mL [19].
Which is better, MK-677 or CJC-1295 ipamorelin?
MK-677 (ibutamoren) is an oral GHSR agonist with a half-life of approximately 4.7 hours; CJC-1295/ipamorelin is an injectable GHRH/GHSR dual combination. The two approaches differ in route, half-life, regulatory status, and available clinical evidence [16]. No direct comparative trial has been published. MK-677 Phase I/II human data are available; CJC-1295/ipamorelin combination data are primarily preclinical and mechanistic.
What is the CJC-1295 dosage used in research?
The Teichman et al. 2006 JCEM Phase II trial used single-dose CJC-1295 DAC at 30, 60, 90, or 125 mcg/kg subcutaneously in healthy adults [1]. Preclinical rodent studies have used 100–500 mcg/kg across multiple routes. No validated human therapeutic dose exists, as CJC-1295 is not FDA-approved. See CJC-1295 DAC vs no DAC for the pharmacokinetic context.
Can taking HGH peptides like CJC-1295 increase height in adolescents?
No studies have examined CJC-1295 in adolescent populations. Growth plate closure timing is governed by estrogen and androgen signaling, not solely GH levels. Extrapolating adult GH-axis research to adolescent height is not supported by the published literature. No clinical basis exists for this application in the CJC-1295 research record.
What happens when CJC-1295 use is discontinued?
No published clinical study has specifically examined GH axis rebound or suppression following CJC-1295 discontinuation. The compound stimulates pituitary GH release rather than replacing it, which suggests endogenous axis preservation in principle, but long-term follow-up data examining post-discontinuation GH dynamics are absent from the literature.
Why does CJC-1295 cause flushing?
Flushing is attributed to the vasodilatory effects of elevated GH and potentially to direct peptide-induced nitric oxide signaling. The Teichman 2006 trial noted transient vasodilatory reactions in human subjects at 90–125 mcg/kg [1]. The mechanism is believed analogous to niacin-flush pathways in peripheral vasculature — peripheral vasodilation causing skin redness and warmth.
Is CJC-1295 considered natural or synthetic?
CJC-1295 is fully synthetic. It was designed and synthesized by ConjuChem Biotechnologies and does not occur in nature [4]. It is an analog of the endogenous peptide GHRH, modified at four positions for protease resistance and, in the DAC form, with an additional maleimide-lysine group for albumin binding. The natural ligand GHRH exists endogenously; CJC-1295 does not.